News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Abingworth Management Ltd. Closes 300 Million Stg Life Sciences Fund
January 29, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON (AFX) - Biomedical venture capital specialist Abingworth said it has closed its 300 mln stg life sciences fund, Abingworth Bioventures V LP, which will invest in biotechnology and medical companies in Europe and the US.
Twitter
LinkedIn
Facebook
Email
Print
Startups
Europe
MORE ON THIS TOPIC
Weight loss
Approvals in Hand, Lilly and Novo Obesity Pills Will Battle It Out on Hairline Differences
April 2, 2026
·
3 min read
·
Annalee Armstrong
Drug pricing
Pharma’s Reluctance To Serve Europe To Dodge MFN Drug Pricing Is Chilling
April 2, 2026
·
3 min read
·
Annalee Armstrong
Layoffs
Layoffs at Novo’s Ex-Catalent Site Despite Signs of Turnaround, Continued Investment
April 1, 2026
·
2 min read
·
Nick Paul Taylor
Business
11 Startups Selected for National Life Sciences Accelerator Program
April 1, 2026
·
2 min read
·
Angela Gabriel
